) shares inched up 1.05% after it announced positive data from a
phase III study evaluating oncology drug, Xalkori, in treatment
naive ALK-positive advanced non-small cell lung cancer (NSCLC)
The phase III, PROFILE 1014 study compared the use of Xalkori
versus standard platinum-based chemotherapy regimens in patients
with advanced NSCLC. The study met its primary endpoint with
Xalkori significantly prolonging progression-free survival (PFS)
as compared to standard platinum-based chemotherapy regimens.
Results from the PROFILE 1014 study are in line with the positive
data from a phase III study (PROFILE 1007) announced in Jun 2012.
PROFILE 1007 showed a significant improvement in PFS in
previously treated patients with advanced ALK-positive NSCLC
Eli Lilly and Company
) Alimta (pemetrexed) or
) Taxotere (docetaxel).
We remind investors that the U.S. Food and Drug Administration
(FDA) had initially granted accelerated approval to Xalkori in
Aug 2011. In Nov 2013, the FDA granted regular approval to
Xalkori for the treatment of patients with metastatic
ALK-positive NSCLC as detected by an FDA-approved test. Xalkori
sales were $282 million in 2013, up 129% y/y.
The encouraging data from the phase III, PROFILE 1014 study on
Xalkori is a positive for Pfizer. We believe this data will
augment Pfizer's label expansion efforts related to Xalkori.
Approval for the treatment-naive NSCLC patient population will
significantly boost the product's commercial potential.
Pfizer carries a Zacks Rank #3 (Hold). Some better-ranked stocks
in the health care sector include
Gilead Sciences Inc.
). The stock carries a Zacks Rank #1 (Strong Buy).
GILEAD SCIENCES (GILD): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.